PR5-LL-CM01

• CAT Number: I034984
• CAS Number: 1005307-86-7
• Molecular Formula: C23H27N7
• Molecular Weight: 401.51
• Purity: ≥95%
• Synonyms: 6-N-[2-(dimethylamino)ethyl]-4-N-(3,4-dimethylphenyl)-1-phenylpyrazolo[3,4-d]pyrimidine-4,6-diamine
• InChI: InChI=1S/C23H27N7/c1-16-10-11-18(14-17(16)2)26-21-20-15-25-30(19-8-6-5-7-9-19)22(20)28-23(27-21)24-12-13-29(3)4/h5-11,14-15H,12-13H2,1-4H3,(H2,24,26,27,28)
• InChIKey: UPAZOMJFUXPAJI-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC2=C3C=NN(C3=NC(=N2)NCCN(C)C)C4=CC=CC=C4)C

PR5-LL-CM01 (Cat No.: I034984) is a small-molecule inhibitor designed to target NF-κB signaling, a central pathway regulating inflammation, immune responses, and cancer progression. By blocking NF-κB activity, PR5-LL-CM01 reduces the transcription of pro-inflammatory cytokines and survival-related genes, making it useful in studying inflammatory diseases and tumor biology. Researchers employ it as a pharmacological probe to explore therapeutic strategies for autoimmune disorders, chronic inflammation, and oncology. Though not approved for clinical use, PR5-LL-CM01 advances understanding of NF-κB–driven mechanisms in biomedical research.

Reference

[1]. Prabhu L, et al. Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers. Oncotarget. 2017;8(25):39963-39977.
[Content Brief]